How do you approach week-2 reassessment and switching if no PRO-2 response after starting infliximab or upadacitinib in MAYO 3 ulcerative colitis?

PMID 41626838 PRO-2 (patient-reported outcome) response, defined as ≥50% reduction in stool frequency and rectal bleeding scores.